Member of the Board since 2013 and Vice Chair since June 2018.
Steen Riisgaard was born in 1951 and is a Danish national. He received an MSc in Microbiology from the University of Copenhagen. He began his career as Research Fellow at Statens Serum Institute (SSI) and Research Microbiologist at Foss Electric, Denmark.
Steen Riisgaard has more than 35 years of experience in industrial biotechnology. He joined the Research & Development team in Novozymes A/S (then Novo Nordisk A/S, Enzymes Division) in 1979. In 1982, he moved to Tokyo to start up a new Enzymes Research & Development unit in the Novo Nordisk subsidiary Novo Industry Japan Ltd. He returned to Denmark in 1985 and held a number of different positions in the company until 1989, where he was promoted to Corporate Executive Vice President of the Enzymes Business. In 2000 Steen Riisgaard became President and CEO of Novozymes A/S, when it was demerged from Novo Nordisk A/S, and served in that position until April 2013.
In addition to the role of Vice Chair of the Board of Novo Holdings A/S, Steen Riisgaard currently serves as Chair of New Xellia Group A/S, based in Denmark. Furthermore, he is Vice Chair of the Board of the Villum Foundation and board member of the Novo Nordisk Foundation, both based in Denmark, as well as board member of Corbion N.V. in the Netherlands.